XSHE
002424
Market cap979mUSD
Sep 30, Last price
4.69CNY
Name
Guizhou Bailing Group Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating within China, Guizhou Bailing Group Pharmaceutical Co., Ltd. specializes in the full spectrum of activities for traditional Chinese medicine, from initial research and development to manufacturing and market distribution. The company provides a diverse portfolio of medicinal preparations, available in numerous forms including tablets, capsules, granules, liquid syrups, pills, powdered formulations, tinctures, sprays, and topical ointments. These remedies are formulated to address a wide range of health concerns, such as cardiovascular and cerebrovascular conditions, common respiratory issues like coughs and colds, and specific pediatric and gynecological disorders. Established in 2005, its primary operational base is situated in Anshun, China.
Key people
Hongxing Li
Chief Financial Officer · since 2020
Jixian Feng
Deputy General Manager · since 2021
Yuanzhen Yuan
Executive Deputy General Manager · since 2022
Maoxue Zheng
Deputy General Manager · since 2021
Wei Jiang
Chairman of the Board, Acting Secretary of the Board · since 2024
Pei Chen
Deputy General Manager, Director · since 2024
Yong Jiang
Director · since 2021
Yifeng Zhou
Director · since 2022
Jian Hu
Independent Director · since 2020
Guowan Yan
Independent Director · since 2023
Ming Yang
Independent Director · since 2023
Hongwu Zhang
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||